Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis - PubMed (original) (raw)
Review
Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis
Phei Ching Lim et al. Daru. 2022 Jun.
Abstract
Purpose: Tocilizumab has shown equivocal outcomes in reducing mortality in COVID-19. The corticosteroids appear to be an affordable alternative to tocilizumab. This study aims to estimate the efficacy of tocilizumab and the corticosteroids particularly dexamethasone and methylprednisolone and to identify possible determinants of their efficacy.
Methods: Five electronic databases were searched for studies involving tocilizumab, dexamethasone, and methylprednisolone in treating COVID-19. We included case-control and randomized or partially randomized trials. Meta-regression for patient baseline characteristics, co-medications, and tocilizumab dose regimens was performed to identify contributing factors to drug efficacy.
Results: Thirteen randomized controlled trials (RCTs) and twenty-four case-control studies were included in our meta-analysis involving 18,702 patients. Meta-analysis among the RCTs showed that a summary estimate favoring mortality reduction (OR 0.71, 95%CI 0.55 - 0.92) contributed mainly by tocilizumab and dexamethasone. Among case-control studies, meta-analysis showed mortality reduction (OR 0.52, 95%CI 0.36 - 0.75) contributed by tocilizumab and tocilizumab-methylprednisolone combination. Methylprednisolone alone did not reduce mortality except for one study involving high dose pulse therapy. Meta-analysis also found that all three drugs did not significantly reduce mechanical ventilation (OR 0.72, 95%CI 0.32 - 1.60).
Conclusion: Tocilizumab and dexamethasone emerge as viable options in reducing mortality in severe COVID-19 patients. A tocilizumab-corticosteroid combination strategy may improve therapeutic outcome in cases where single therapy fails.
Keywords: COVID-19; Dexamethasone; Meta-analysis; Methylprednisolone; Tocilizumab.
© 2022. Springer Nature Switzerland AG.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1
Flow chart for study screening and selection according to PRISMA guidelines
Fig. 2
Forest plot for the effect for all treatments (tocilizumab, methylprednisolone, and dexamethasone) on mortality in randomised controlled trials
Fig. 3
Forest plot for the effect of all treatments (tocilizumab, methylprednisolone, and dexamethasone) on mortality in case–control studies
Fig. 4
Forest plot for the effect of tocilizumab alone on mortality
Fig. 5
Forest plot for effect of all treatments (tocilizumab, methylprednisolone, and dexamethasone) on the event of invasive mechanical ventilation
Fig. 6
Funnel plot for (a) randomised clinical trials, and (b) case–control studies included in the meta-analysis
Similar articles
- Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials.
Sterne JAC, Diaz J, Villar J, Murthy S, Slutsky AS, Perner A, Jüni P, Angus DC, Annane D, Azevedo LCP, Du B, Dequin PF, Gordon AC, Green C, Higgins JPT, Horby P, Landray MJ, Lapadula G, Le Gouge A, Leclerc M, Savović J, Tomazini B, Venkatesh B, Webb S, Marshall JC; WHO COVID-19 Clinical Management and Characterization Working Group. Sterne JAC, et al. Trials. 2020 Aug 24;21(1):734. doi: 10.1186/s13063-020-04641-3. Trials. 2020. PMID: 32831155 Free PMC article. - Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19.
Abbasian L, Toroghi N, Rahmani H, Khalili H, Hasannezhad M, Ghiasvand F, Jafari S, Salehi M, Salahshour F, Azadbakhsh Kanaf Gorabi M, Alizade F, Ghaderkhani S, Nakhostin M. Abbasian L, et al. Int Immunopharmacol. 2022 Jun;107:108689. doi: 10.1016/j.intimp.2022.108689. Epub 2022 Mar 17. Int Immunopharmacol. 2022. PMID: 35313272 Free PMC article. - Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Snow TAC, et al. Intensive Care Med. 2021 Jun;47(6):641-652. doi: 10.1007/s00134-021-06416-z. Epub 2021 May 21. Intensive Care Med. 2021. PMID: 34019122 Free PMC article. - Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.
Mahroum N, Watad A, Bridgewood C, Mansour M, Nasr A, Hussein A, Khamisy-Farah R, Farah R, Gendelman O, Lidar M, Shoenfeld Y, Amital H, Kong JD, Wu J, Bragazzi NL, McGonagle D. Mahroum N, et al. Int J Environ Res Public Health. 2021 Aug 30;18(17):9149. doi: 10.3390/ijerph18179149. Int J Environ Res Public Health. 2021. PMID: 34501738 Free PMC article. Review. - Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
Kyriakopoulos C, Ntritsos G, Gogali A, Milionis H, Evangelou E, Kostikas K. Kyriakopoulos C, et al. Respirology. 2021 Nov;26(11):1027-1040. doi: 10.1111/resp.14152. Epub 2021 Oct 3. Respirology. 2021. PMID: 34605114 Free PMC article. Review.
Cited by
- Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence.
Rezabakhsh A, Mojtahedi F, Tahsini Tekantapeh S, Mahmoodpoor A, Ala A, Soleimanpour H. Rezabakhsh A, et al. Arch Acad Emerg Med. 2024 May 9;12(1):e47. doi: 10.22037/aaem.v12i1.2217. eCollection 2024. Arch Acad Emerg Med. 2024. PMID: 38994467 Free PMC article. - Effect of anti-inflammatory drugs on the storm of inflammatory factors in respiratory tract infection caused by SARS-CoV-2: an updated meta-analysis.
Qin Z, Li Y, Sun W, Lu Y, Zhang N, Yang R, Liu Y, Tang L, Liu Q. Qin Z, et al. Front Public Health. 2023 Oct 2;11:1198987. doi: 10.3389/fpubh.2023.1198987. eCollection 2023. Front Public Health. 2023. PMID: 37920591 Free PMC article. - Long-Term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics.
Sahebkar A, Jamialahmadi T, Rahmoune H, Guest PC. Sahebkar A, et al. Adv Exp Med Biol. 2023;1412:27-49. doi: 10.1007/978-3-031-28012-2_2. Adv Exp Med Biol. 2023. PMID: 37378760 Review. - Association of Polymorphisms of IL-6 Pathway Genes (IL6, IL6R and IL6ST) with COVID-19 Severity in an Amazonian Population.
Rodrigues FBB, da Silva R, Santos EFD, de Brito MTFM, da Silva ALS, de Meira Leite M, Póvoa da Costa F, de Nazaré do Socorro de Almeida Viana M, de Sarges KML, Cantanhede MHD, Veríssimo AOL, Carvalho MDS, Henriques DF, Silva CPD, Costa IB, Nunes JAL, Costa IB, Viana GMR, Queiroz MAF, Lima SS, Lopes JDC, Torres MKDS, Vallinoto IMVC, Bichara CDA, Vallinoto ACR, Santos EJMD. Rodrigues FBB, et al. Viruses. 2023 May 19;15(5):1197. doi: 10.3390/v15051197. Viruses. 2023. PMID: 37243282 Free PMC article. - Artificial-Intelligence-Driven Algorithms for Predicting Response to Corticosteroid Treatment in Patients with Post-Acute COVID-19.
Myska V, Genzor S, Mezina A, Burget R, Mizera J, Stybnar M, Kolarik M, Sova M, Dutta MK. Myska V, et al. Diagnostics (Basel). 2023 May 16;13(10):1755. doi: 10.3390/diagnostics13101755. Diagnostics (Basel). 2023. PMID: 37238239 Free PMC article.
References
- The John Hopkins Coronavirus Resource Center. Cumulative cases. In: The John Hopkins Coronavirus Resource Center. The John Hopkins and Medicine System. 2021. https://coronavirus.jhu.edu/data/cumulative-cases. Accessed 15 January 2021.
- Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233–1244. doi: 10.1016/S2213-2600(20)30404-5. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources